Management of Persistent Fever in Rheumatoid Arthritis

Diagnostic Confirmation and Initial Management

The American College of Rheumatology recommends performing ultrasonography of joints to confirm inflammatory synovitis in patients with rheumatoid arthritis and persistent fever, as traditional composite indices may be unreliable in this context 1
The European League Against Rheumatism suggests considering alternative diagnoses that can mimic RA activity, such as crystal arthropathies, polymyalgia rheumatica, and vasculitis, in patients with persistent fever and negative infectious workup 1
The American College of Rheumatology recommends initiating systemic glucocorticoids immediately as first-line therapy for RA patients with active systemic features, including persistent fever, to provide rapid control of systemic inflammation and fever 2
The American College of Rheumatology advises against continuing NSAID monotherapy beyond 1 month in patients with active fever, as this is inappropriate, and recommends initiating systemic glucocorticoids instead 2

The American College of Rheumatology recommends initiating anakinra (IL-1 receptor antagonist) if fever persists despite systemic glucocorticoids within 1-2 weeks, as anakinra is specifically recommended for all RA patients with active fever and features of poor prognosis 2
The American College of Rheumatology advises against initiating methotrexate as initial management for patients with active fever without active arthritis, as this is inappropriate 2

The Infectious Diseases Society of America recommends against empirically adding vancomycin or other antibiotics for persistent fever in a stable patient with confirmed negative infectious workup, as this provides no benefit 3
The American College of Rheumatology advises against escalating DMARD therapy if inflammatory activity cannot be confirmed, as this leads to apparent treatment failure and unnecessary toxicity 1

The American College of Rheumatology recommends performing daily clinical evaluation if hospitalized, looking for new symptoms or signs that might indicate infection or other complications, and reassessing disease activity regularly using composite measures (DAS28, SDAI, or CDAI) until treatment target is reached 3
The American College of Rheumatology notes that the median time to defervescence with appropriate therapy is typically 2-5 days, and persistent fever alone in a stable patient is rarely an indication to alter the regimen 3

Escalating immunosuppression in the setting of occult infection increases mortality, according to the American College of Physicians, as stated by the Mayo Clinic Proceedings 4

The European League Against Rheumatism recommends confirming the presence or absence of true inflammatory disease activity before any treatment adjustment, as published in the Annals of the Rheumatic Diseases 5
Clinical assessment, including examination for objective synovitis, is crucial in diagnosing fever in RA patients, as suggested by the American College of Rheumatology, with guidance from Praxis Medical Insights 6

The American College of Rheumatology recommends initiating systemic glucocorticoids as the first-line treatment for RA patients with active systemic features, including fever, as stated in Arthritis Care & Research 7, 8, 9
Glucocorticoids provide rapid control of systemic inflammation and fever, according to the American College of Rheumatology, as published in Arthritis Care & Research 7, 8

The American College of Rheumatology suggests that if fever persists despite glucocorticoids, escalation to biologic therapy, such as anakinra, may be necessary, as stated in Arthritis Care & Research 7, 8, 9

The American College of Rheumatology recommends reassessing disease activity every 1-3 months until treatment target is reached, using composite disease activity measures, such as DAS28, SDAI, or CDAI, as suggested by the Mayo Clinic Proceedings and Praxis Medical Insights 4, 6